Last updated on April 2017

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer


Brief description of study

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Clinical Study Identifier: NCT02857270

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Manish Patel

Florida Cancer Specialists
Sarasota, FL United States
  Connect »

Ryan Sullivan

Massachusetts General Hospital
Boston, MA United States
  Connect »

SMO Sarah Cannon Research Inst.

Sarah Cannon Cancer Center
Nashville, TN United States
  Connect »

Johanna Bendell

Tennessee Oncology PLLC
Nashville, TN United States
  Connect »

Shubham Pant

University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Nedlands, Australia
  Connect »

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Sydney, Australia
  Connect »

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Villejuif, France
  Connect »